Top

Published in:

Open Access 01-12-2018 | Research article

Clinical features and dysfunctions of iron metabolism in Parkinson disease patients with hyper echogenicity in substantia nigra: a cross-sectional study

Authors: Shu-yang Yu, Chen-jie Cao, Li-jun Zuo, Ze-jie Chen, Teng-hong Lian, Fang Wang, Yang Hu, Ying-shan Piao, Li-xia Li, Peng Guo, Li Liu, Qiu-jin Yu, Rui-dan Wang, Piu Chan, Sheng-di Chen, Xiao-min Wang, Wei Zhang

Published in: BMC Neurology | Issue 1/2018

Abstract

Background

Transcranial ultrasound is a useful tool for providing the evidences for the early diagnosis and differential diagnosis of Parkinson disease (PD). However, the relationship between hyper echogenicity in substantia nigra (SN) and clinical symptoms of PD patients remains unknown, and the role of dysfunction of iron metabolism on the pathogenesis of SN hyper echogenicity is unclear.

Methods

PD patients was detected by transcranial sonography and divided into with no hyper echogenicity (PDSN-) group and with hyper echogenicity (PDSN+) group. Motor symptoms (MS) and non-motor symptoms (NMS) were evaluated, and the levels of iron and related proteins in serum and cerebrospinal fluid (CSF) were detected for PD patients. Data comparison between the two groups and correlation analyses were performed.

Results

PDSN+ group was significantly older, and had significantly older age of onset, more advanced Hohen-Yahr stage, higher SCOPA-AUT score and lower MoCA score than PDSN- group (P < 0.05). Compared with PDSN- group, the levels of transferrin and light-ferritin in serum and iron level in CSF were significantly elevated (P < 0.05), but ferroportin level in CSF was significantly decreased in PDSN+ group (P < 0.05).

Conclusions

PD patients with hyper echogenicity in SN are older, at more advanced disease stage, have severer motor symptoms, and non-motor symptoms of cognitive impairment and autonomic dysfunction. Hyper echogenicity of SN in PD patients is related to dysfunction of iron metabolism, involving increased iron transport from peripheral system to central nervous system, reduction of intracellular iron release and excessive iron deposition in brain.

Braak H, Del Tredici K, Rub U, de Vos RA, Jansen Steur EN, Braak E. Staging of brain pathology related to sporadic Parkinson's disease. Neurobiol Aging. 2003;24(2):197–211.CrossRefPubMed

Behnke S, Berg D, Naumann M, Becker G. Differentiation of Parkinson's disease and atypical parkinsonian syndromes by transcranial ultrasound. J Neurol Neurosurg Psychiatry. 2005;76(3):423–5.CrossRefPubMedPubMedCentral

Berg D, Merz B, Reiners K, Naumann M, Becker G. Five-year follow-up study of hyperechogenicity of the substantia nigra in Parkinson's disease. Mov Disord. 2005;20(3):383–5.CrossRefPubMed

Berg D, Becker G, Zeiler B, Tucha O, Hofmann E, Preier M, Benz P, Jost W, Reiners K, Lange KW. Vulnerability of the nigrostriatal system as detected by transcranial ultrasound. Neurology. 1999;53(5):1026–31.CrossRefPubMed

Bartova P, Skoloudik D, Ressner P, Langova K, Herzig R, Kanovsky P. Correlation between substantia nigra features detected by sonography and Parkinson disease symptoms. J Ultrasound Med. 2010;29(1):37–42.CrossRefPubMed

Zhou HY, Sun Q, Tan YY, Hu YY, Zhan WW, Li DH, Wang Y, Xiao Q, Liu J, Chen SD. Substantia nigra echogenicity correlated with clinical features of Parkinson's disease. Parkinsonism Relat Disord. 2016;24:28–33.CrossRefPubMed

Hughes AJ, Daniel SE, Kilford L, Lees AJ. Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases. J Neurol Neurosurg Psychiatry. 1992;55(3):181–4.CrossRefPubMedPubMedCentral

Bartova P, Skoloudik D, Bar M, Ressner P, Hlustik P, Herzig R, Kanovsky P. Transcranial sonography in movement disorders. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2008;152(2):251–8.CrossRefPubMed

Becker G, Seufert J, Bogdahn U, Reichmann H, Reiners K. Degeneration of substantia nigra in chronic Parkinson's disease visualized by transcranial color-coded real-time sonography. Neurology. 1995;45(1):182–4.CrossRefPubMed

10.

Saunders-Pullman R. Estrogens and Parkinson disease: neuroprotective, symptomatic, neither, or both? Endocrine. 2003;21(1):81–7.CrossRefPubMed

11.

Sawada H, Shimohama S. Estrogens and Parkinson disease: novel approach for neuroprotection. Endocrine. 2003;21(1):77–9.CrossRefPubMed

12.

Schweitzer KJ, Behnke S, Liepelt I, Wolf B, Grosser C, Godau J, Gaenslen A, Bruessel T, Wendt A, Abel F, et al. Cross-sectional study discloses a positive family history for Parkinson's disease and male gender as epidemiological risk factors for substantia nigra hyperechogenicity. J Neural Transm (Vienna). 2007;114(9):1167–71.CrossRef

13.

McGeer PL, McGeer EG. Glial reactions in Parkinson's disease. Mov Disord. 2008;23(4):474–83.CrossRefPubMed

14.

Gao HM, Hong JS, Zhang W, Liu B. synergistic dopaminergic neurotoxicity of the pesticide rotenone and inflammogen lipopolysaccharide: relevance to the etiology of Parkinso’s disease. J Neurosci. 2003;23(4):1228–36.PubMed

15.

Zecca L, Zucca FA, Albertini A, Rizzio E, Fariello RG. A proposed dual role of neuromelanin in the pathogenesis of Parkinson's disease. Neurology. 2006;67(7 Suppl 2):S8–11.CrossRefPubMed

16.

Stenc Bradvica I, Mihaljevic I, Butkovic-Soldo S, Kadojic D, Titlic M, Bradvica M, Kralik K. Transcranial sonography and the pocket smell test in the differential diagnosis between parkinson's disease and essential tremor. Neurol Sci. 2015;36(8):1403–10.CrossRefPubMed

17.

Zhang W, Yan ZF, Gao JH, Sun L, Huang XY, Liu Z, Yu SY, Cao CJ, Zuo LJ, Chen ZJ, et al. Role and mechanism of microglial activation in iron-induced selective and progressive dopaminergic neurodegeneration. Mol Neurobiol. 2014;49(3):1153–65.CrossRefPubMed

18.

Peron J, Vicente S, Leray E, Drapier S, Drapier D, Cohen R, Biseul I, Rouaud T, Le Jeune F, Sauleau P, et al. Are dopaminergic pathways involved in theory of mind? A study in Parkinson's disease. Neuropsychologia. 2009;47(2):406–14.CrossRefPubMed

19.

Gaasch JA, Lockman PR, Geldenhuys WJ, Allen DD, Van der Schyf CJ. Brain iron toxicity: differential responses of astrocytes, neurons, and endothelial cells. Neurochem Res. 2007;32(7):1196–208.CrossRefPubMed

20.

Belaidi AA, Bush AI. iron neurochemistry in Alzheimer's disease and Parkinson's disease: targets for therapeutics. J Neurochem. 2015;

Title: Clinical features and dysfunctions of iron metabolism in Parkinson disease patients with hyper echogenicity in substantia nigra: a cross-sectional study
Authors: Shu-yang Yu
Chen-jie Cao
Li-jun Zuo
Ze-jie Chen
Teng-hong Lian
Fang Wang
Yang Hu
Ying-shan Piao
Li-xia Li
Peng Guo
Li Liu
Qiu-jin Yu
Rui-dan Wang
Piu Chan
Sheng-di Chen
Xiao-min Wang
Wei Zhang
Publication date: 01-12-2018
Publisher: BioMed Central
Published in: BMC Neurology / Issue 1/2018
Electronic ISSN: 1471-2377
DOI: https://doi.org/10.1186/s12883-018-1016-5

ACC 2024 Congress

Springer Medicine

Clinical features and dysfunctions of iron metabolism in Parkinson disease patients with hyper echogenicity in substantia nigra: a cross-sectional study

Abstract

Background

Methods

Results

Conclusions

ACC 2024 Congress

Springer Medicine

Abstract

Background

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 1/2018

Altered development of dopaminergic neurons differentiated from stem cells from human exfoliated deciduous teeth of a patient with Down syndrome

Transient increase in CSF GAP-43 concentration after ischemic stroke

Pediatric multiple sclerosis: a review

Personalized objects can optimize the diagnosis of EMCS in the assessment of functional object use in the CRS-R: a double blind, randomized clinical trial

First three cases of scalp temperature change in symptomatic areas affected by nummular headache: a case report

Effect of tendon vibration during wide-pulse neuromuscular electrical stimulation (NMES) on muscle force production in people with spinal cord injury (SCI)